First in Human Study of ALS-002158; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C Genotype 1

Inclusion Criteria: * Subject has provided written consent. * Subject is in good health as deemed by the investigator * Creatinine clearance of greater than 50 mL/min (Cockcroft- Gault). * Male or female, 18-55 years of age for HV and 18-65 years of age for subjects with CHC. * Body mass index (BMI) 18-32 kg/m2 inclusive for HV and 18-36 kg/m2 for subjects with CHC, minimum weight 50 kg in both populations. * A female is eligible to participate in this study if she is of non-childbearing potential. * If male, subject is surgically sterile or practicing specific forms of birth control. Additional inclusion criteria for subjects with CHC genotype 1 infection: * Positive HCV antibody and a positive HCV RNA at screening. * Documentation of CHC infection of greater than 6 months duration at screening. * CHC genotype 1 infection at screening. * HCV RNA viral load ≥ 105 and ≤ 108 IU/mL using a sensitive quantitative assay * Liver biopsy within two years or Fibroscan evaluation within 6 months prior to screening that clearly excludes cirrhosis. Fibroscan liver stiffness score must be \< 12 kPa. * Absence of hepatocellular carcinoma as indicated by an abdominal ultrasound scan during screening. * No prior treatment for CHC. * Absence of history of clinical hepatic decompensation. * Laboratory values include: * prothrombin time \< 1.5 × ULN. * platelets \> 120,000/mm3. * albumin \> 3.5 g/dL, bilirubin \< 1.5 mg/dL at screening (subjects with documented Gilbert's disease allowed). * Serum ALT concentration \< 5 × ULN. * Alpha Fetoprotein (AFP) concentration ≤ ULN. If AFP is ≥ ULN, absence of a hepatic mass must be demonstrated by ultrasound within the screening period. Exclusion Criteria: * Clinically significant cardiovascular, respiratory, renal, gastrointestinal, hematologic, neurologic, thyroid, or any uncontrolled medical illness or psychiatric disorder. * Positive test for HAV IgM, HBsAg, HCV Ab (HV only), or HIV Ab. * Abnormal screening laboratory results that are considered clinically significant by the investigator. * Clinically significant drug allergy such as, but not limited to, sulfonamides and penicillins, including those experienced in previous trials with experimental drugs. * Participation in an investigational drug trial or having received an investigational vaccine within 30 days or 5 half lives (whichever is longer) prior to receiving study medication. * Clinically significant blood loss or elective blood donation of significant volume. * Laboratory abnormalities including: * Thyroid Stimulating Hormone (TSH) \>ULN. * Hematocrit \< 34 %. * White blood cell counts \< 3,500/mm3. * For healthy volunteers, history of regular use of tobacco. * The subject has a positive pre-study drug screen.